SpyGlass Pharma, a late-stage biopharmaceutical company, has priced its initial public offering (IPO) at $16.00 per share. The company is offering 9,375,000 shares of common stock, aiming to raise approximately $150 million before expenses. Additionally, underwriters have a 30-day option to purchase up to 1,406,250 more shares at the same price, less commissions.
The company’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “SGP” on February 6, 2026. The IPO is anticipated to close on February 9, 2026, pending customary closing conditions.
**Why this matters**
The IPO will provide SpyGlass Pharma with capital to support its late-stage biopharmaceutical development efforts. Listing on the Nasdaq Global Select Market increases the company’s visibility and access to public investors, which can be critical for funding ongoing research and development activities.
Source: NewsData